BOT - Anything but charting, page-7781

you may be right but personally I would follow the money. The revenue from a best in class ACNE drug would potentially outstrip a nasal spray for pre / post surgical patients - population of image driven pimply teens as opposed to surgical patients not taking into account repeat or consistent users.
Without knowing what the pricing of the ACNE drug the sheer size of the ACNE market would blow the revenue from Sofdra out of the water. There's also the prospect with funding from Sofdra these trials could run concurrently. Imagine the SP with 2 best in class drugs and 1 without a competitor. I think i'll hang onto my shares a wee bit longer - these opportunities don't come along all that often if all goes to plan.
Happy Easter everyone.